• Vor Bio expanded its RemeGen partnership to license RC298, a long-acting dual BAFF/APRIL inhibitor, exclusively outside Greater China.
• Upfront consideration totals approximately $56 million: $10 million cash and pre-funded warrants for 2,300,000 shares valued at approximately $46 million.
• RemeGen could receive up to $300 million in development milestones, including $20 million for initial clinical development and technology transfer milestones.
• A Chinese regulatory filing is expected in the first half of 2027; RemeGen will lead preclinical and Phase 1 development in China.
• Following Phase 1, Vor will assume subsequent clinical development, regulatory activities and commercialization outside Greater China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9876155) on November 12, 2026, and is solely responsible for the information contained therein.